Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 2/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984059 | 0.87 | KDM4E (0.37) | — | |
| SCHEMBL982519 | 0.80 | LIPG (0.39) | HSD11B1LIPGTSHRNR1H3TYR | |
| SCHEMBL11191124 | 0.79 | ALDH1A1 (0.43) | TSHRCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL983062 | 0.76 | SMN1; SMN2 (0.33) | GCGRADORA3 | |
| SCHEMBL817129 | 0.75 | TYR (0.36) | LIPGTSHRTYRTLR8CYP3A4 | |
| SCHEMBL981932 | 0.75 | LIPG (0.45) | HSD11B1LIPGTSHRNR1H3TYR | |
| SCHEMBL983505 | 0.74 | LIPG (0.47) | LIPGTSHRNR1H3TYRGPR84 | |
| SCHEMBL8566183 | 0.74 | LIPG (0.47) | LIPGTSHRNR1H3TYRGPR84 | |
| SCHEMBL17802345 | 0.74 | LIPG (0.47) | LIPGTSHRNR1H3TYRGPR84 | |
| SCHEMBL430510 | 0.74 | TYR (0.35) | LIPGTSHRTYRTLR8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275406-B1 | PROCESS FOR PRODUCING ISOCYANATE | ASAHI CHEMICAL IND (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-9233918-B2 | Isocyanate production process | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| US-20110092731-A1 | ISOCYANATE PRODUCTION PROCESS | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2275406-A1 | PROCESS FOR PRODUCING ISOCYANATE | Asahi Kasei Chemicals Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092731-A1 | ISOCYANATE PRODUCTION PROCESS | CPS1, PHGDH, APEH | HSD11B1 2188/4885LIPG 28/4885TSHR 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.